ClinicalTrials.gg
RecruitingNCT05289167Updated Nov 19, 2026

Post-Transplant Cyclophosphamide, Bortezomib and Abatacept for the Prevention of Graft-versus-Host-Disease (GvHD)

A Phase 1/2 interventional study of Cyclophosphamide and Abatacept in Graft-versus-host Disease, sponsored by Northwell Health. Recruiting at 1 site in United States. Open to participants aged 14 Years to 100 Years. Per ClinicalTrials.gov, last updated 2026-11-19.

Sponsored by Northwell Health · Phase 1/2, Interventional, and Treatment

How we know

From the registry’s dates

  • Started Mar 2022; still recruiting 4 years 8 months later.
Updated Nov 19, 2026Primary completion movedGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1/2
Study type
Interventional
Enrollment
74
Allocation
Not applicable
Ages
14 Years to 100 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-21

Among 48 studies testing cyclophosphamide in Graft vs Host Disease — 11 open to participants now, 22 under way, 4 of them phase 3. Cyclophosphamide · Graft vs Host Disease.

Planned enrollment
10th of 47
74 · median 35
Started
2022
with 3 others
Phase 1/2
9 of 48
1 open now
Primary completion
2027-11
later than 11 of 21 live
Registered
37th of 48
by date

Among the 48 studies testing cyclophosphamide in Graft vs Host Disease, this one is the 10th largest by planned enrollment of the 47 interventional ones that give a count, is one of 4 that started in 2022, is one of 9 in phase 1/2, reaches primary completion later than 11 of the 21 other live ones, and was the 37th registered.

Graft vs Host Disease

804 studies on the registry are indexed under Graft vs Host Disease; 147 are open to participants now.

Browse Graft vs Host Disease studies →

Open to participants now

11 of the 48 studies testing cyclophosphamide in Graft vs Host Disease are open now, in 12 countries. Recruiting first, the newest first:

5 more — sign in →

By country, each count listing its studies:

All 11 open studies →

About cyclophosphamide

Cyclophosphamide: first FDA approval 1959 (CYTOXAN). What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 101 Graft vs Host Disease studies recruiting now, 51 (50%) set no upper age limit and 40 (40%) stop at 75 or younger; 42 take children under 18; 9 take healthy volunteers.

This study: 14 Years to 100 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 48 studies testing cyclophosphamide in Graft vs Host Disease, or all of them as a file.
02

Study summary

This is a phase I-II clinical trial. Adult subjects with hematological malignancies undergoing allogeneic HSCT from an HLA matched sibling or ≥7 out of 8 allele level HLA matched unrelated donor are eligible for the study if they meet the criteria defined in our standard operation procedures (SOPs), meet all inclusion criteria, and do not satisfy any exclusion criteria. Subjects will receive a standard of care conditioning regimen. Subjects will receive investigational PTCy, investigational bortezomib and investigational abatacept as GvHD prophylaxis.

Read the detailed description

The study will have a phase I and phase II potions. The phase I portion will employ a 3+3 dose escalation design to define the maximum tolerated dose (MTD) of abatacept added to PTCy and bortezomib following HSCT. The phase II portion will consist of two single arm, open label, optimal 2-stage Simon design studies conducted in two separate strata for HLA matched and HLA mismatched donor transplants. Adult patients with hematological malignancies undergoing allogeneic HSCT from an HLA matched sibling or ≥7 out of 8 allele level HLA matched unrelated donor are eligible for the study if they meet the standard criteria defined in our institutional standard operation procedures (SOPs), meet all inclusion criteria, and do not satisfy any exclusion criteria. Subjects will receive a standard of care conditioning regimen followed by peripheral blood hematopoietic stem cells. Subjects with unrelated donors will also receive rabbit anti-thymocyte globulin (rATG). Subjects will receive investigational PTCy, investigational bortezomib and investigational abatacept as GvHD prophylaxis. The phase II portion dose of abatacept will be the MTD as determined in the phase I portion of the study. In the phase II portions, subjects will be stratified based on whether they receive a matched sibling or matched unrelated (matched) donor transplant and ≥7 out of 8, allele level matched (mismatched) unrelated donor transplant.

03

Conditions studied

  • Graft-versus-host Disease

Browse trials for

Keywords

  • GvHD, post transplant cyclophosphamide, abatacept
04

Who can participate

Ages eligible
14 Years to 100 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Age ≥14 years
  • score ≥70%
  • No evidence of progressive bacterial, viral, or fungal infection
  • >50 mL/min/1.72m2
  • and AST \<3 x the
  • Total \<2 x the upper limit of normal (except for Gilbert's syndrome)
  • Alkaline phosphatase ≤250 IU/L
  • (LVEF) >45%
  • Adjusted Carbon Monoxide Diffusing Capacity (DLCO) >50%
  • Negative serology
  • Negative pregnancy test: Confirmation per negative serum β-human chorionic gonadotropin (β-hCG)
  • Willing to comply with all study procedures and be available for the duration of the study.

Exclusion criteria

Exclusion Criteria:

  • Pregnant or nursing females or women of reproductive capability who are unwilling to completely abstain from heterosexual sex or practice 2 effective methods of from start of conditioning through 90 days after the last dose of study drug. A woman of reproductive capability is one who has not undergone a hysterectomy (removal of the womb), has not had both ovaries removed, or has not been (stopped menstrual periods) for more than 24 months in a row.
  • Male subjects who refuse to practice effective barrier contraception from the start of conditioning through a minimum of 90 days after the last dose of study drug, or completely abstain from heterosexual intercourse. This must be done even if they are surgically sterilized (i.e., post-vasectomy).
  • Inability to provide .
  • Patient had myocardial infarction within 6 months prior to enrollment or has (NYHA) Class III or IV heart failure (see Appendix D), uncontrolled angina, severe uncontrolled ventricular arrhythmias, or electrocardiographic evidence of acute ischemia or active conduction system abnormalities. Prior to study entry, any abnormality at screening must be documented by the investigator as not medically relevant.
  • Known allergies to any of the components of the treatment regimen.
  • Serious medical or psychiatric illness likely to interfere with participation in this clinical study.
  • Diagnosed or treated for another within 3 years of enrollment, with the exception of complete resection of basal cell carcinoma or squamous cell carcinoma, an in-situ malignancy, or low-risk prostate cancer after curative therapy.
  • Participation in clinical trials with other investigational agents not included in this trial, within 14 days of the start of this trial and throughout the duration of this trial.
  • Prisoners
  • Pregnant women
Terms in these criteria, in plain language(14)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Karnofsky performance status (KPS)

A 0–100 scale of how well someone can carry out everyday activities. 100 is no complaints and no signs of illness; 70 is able to look after yourself but not to work or keep up normal activity; 50 is needing considerable help and frequent medical care.

Studies often ask for 60 or 70 and above. Your doctor gives the score.

Creatinine clearance (CrCl)

How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

LVEF (left ventricular ejection fraction)

The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Postmenopausal

Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

NYHA class (heart failure)

The New York Heart Association’s four classes of how much heart failure limits physical activity.

I
No limits: ordinary activity causes no undue tiredness or breathlessness.
II
Slight limits: comfortable at rest, ordinary activity causes symptoms.
III
Marked limits: comfortable at rest, less than ordinary activity causes symptoms.
IV
Symptoms even at rest; any activity makes them worse.

Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

05

Study design

Phase
Phase 1 / Phase 2
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
74 participants (estimated)

Study arms

  • Experimental
    Participants with hematological malignancies

    Participants undergoing Allogeneic Hematopoietic Stem Cell Transplantation (HSCT) will receive a combination of cyclophosphamide, known commercially as Cytoxan®, abatacept, known as Orecia® and bortezomib commercially known as Velcade®, to reduce the rate of graft-versus-host disease (GvHD). These medications will be given for GvHD prevention during the transplant process.

    Drug: Cyclophosphamide · Drug: Abatacept · Drug: Bortezomib

Interventions

  • 37.5 mg/kg IV over 1 hour on Day +3 and +4

    Also known as: Cytoxan®

  • Dose level 0: 10 mg/kg IV over 30-60 minutes on day +5 Dose level 1: 10mg/kg IV over 30-60 minutes on day +5 and +14 Dose level 2: 10mg/kg IV over 30-60 minutes on day +5, +14, and +28

    Also known as: Orecia®

  • 1.3 mg/m2 IV 6 hours after graft infusion completion and 72 hours thereafter.

    Also known as: Velcade®

06

What researchers measure

Primary outcomes

  1. Phase I:Incidence Dose limiting toxicity (DLT)

    Defined as grade 4 non-hematologic toxicity affecting the oral cavity, gastrointestinal tract, lung, heart, liver, kidney, bladder, or central nervous system.

    Time frame: Day+1 to Day +120

  2. Phase II: Grades II-IV Acute GvHD

    The first day of grades II-IV acute GvHD will be recorded for that grade. This end point will be evaluated through day +120 post-transplant.

    Time frame: Day+1 to Day +120

Secondary outcomes

  1. Chronic GvHD

    The diagnosis of chronic GvHD is based on clinical and pathological evaluation by the principal investigator in collaboration with the treating physician.The analysis will be based on the maximum grade of chronic GvHD

    Time frame: Day +1 to Day +365

  2. Primary graft failure

    Incidence of graft failure will be calculated from date of transplant to failure for all subjects who receive a transplant and any prophylactic treatment and from date of completion of prophylactic treatment for all participants that completed treatment

    Time frame: Day +1 to Day +30

  3. Poor graft function

    Incidence of poor graft function will be calculated, from date of transplant to failure for all subjects who receive a transplant and any prophylactic treatment and from date of completion of prophylactic treatment for all participants that completed treatment

    Time frame: Day +1 to Day +30

  4. Secondary graft failure

    Evaluated after engraftment is achieved will be calculated from date of engraftment for all subjects with engraftment

    Time frame: Day +1

  5. Treatment-related mortality (TRM)

    Analyzed based on participants that who received a transplant with any prophylactic treatment and for all subjects who received a transplant and completed prophylactic treatment.

    Time frame: Day +1 to Day +730

  6. Relapse rate (RR)

    Evaluated to day +730 and will be analyzed for all subjects who received a transplant and for all transplanted subjects that completed treatment

    Time frame: Day +1 to Day +730

  7. GvHD and relapse-free survival (GRFS)

    Evaluated to day +730 and considers as successes participants that are without reported GvHD III-IV acute GvHD, chronic GvHD requiring systemic therapy and have not experienced relapse or death after transplant

    Time frame: Day +1 to Day +730

  8. Overall survival (OS)

    Evaluated to day +730 and considers all participants who received a transplant and for all transplanted subjects who completed prophylactic treatment

    Time frame: Day +1 to Day +730

07

Study locations

1 of 1 sites recruiting
08

References and documents

Individual participant data

Plan to share: No — Information only to approved study team

No publications or documents are linked to this record.

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedDate before it movedWhere the date was before it movedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Mar 2022 (actual). Primary completion is estimated for Nov 2027, 68 months after the start.

Of 39 phase 1/2 interventional studies under Graft vs Host Disease, half reached primary completion within 55 months of starting (the median), counting those still running; a quarter within 35 and three quarters within 76. This study's planned 68 months is above that.

Primary completion moved once since we started tracking on Sep 25, 2026: Aug 2026 → Nov 2027, on Nov 19, 2026.

Earlier changes are on the record history on ClinicalTrials.gov ↗

How these figures are worked out, and which studies are left out of them.

Registered
Mar 10, 2022
First posted
Mar 21, 2022
StartActual
Mar 13, 2022
Primary completionEst.
Nov 2027was Aug 2026
CompletionEst.
Aug 2028
Last update
Nov 19, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Primary completion
Aug 2026→Nov 2027
Nov 19, 2026
Show all 1 update
  1. Nov 19, 2026
    Primary completion Aug 2026→Nov 2027
    + 1 other change: identifiers

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT05289167
Lead sponsor
Northwell Health
Responsible party
Sponsor
First posted
Mar 21, 2022
Start date
Mar 13, 2022
Primary completion
Nov 2027 (estimated)
Completion
Aug 2028 (estimated)
Last update
Nov 19, 2026

Study contacts

Kelli Cole
Contact
kcole5@northwell.edu
516-734-8973
Angie Fleury
Contact
AFleury2@northwell.edu
516-734-8973
A. Samer Al-Homsi, MD, MBA
principal investigator · Northwell Health

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Cyclophosphamide · Abatacept · Bortezomib

Start the discussion